Emerging evidence underscores the clinical and phenotypic importance of specific mutations in T-LGL leukemia, particularly activator of transcription 3 (STAT3), which is prevalent in CD8+ T-LGL and gamma/delta T-LGL leukemias and has been shown to correlate with neutropenia and poor overall survival. The gene discussed is STAT3; the disease is Decreased total neutrophil count.